Global iPSC-Derived Dopaminergic Neuron Therapy Market Growth (Status and Outlook) 2026-2032
The global iPSC-Derived Dopaminergic Neuron Therapy market size is predicted to grow from US$ 3.91 million in 2025 to US$ 486 million in 2032; it is expected to grow at a CAGR of 63.5% from 2026 to 2032.
iPSC-Derived Dopaminergic Neuron Therapy refers to a regenerative cell therapy approach in which induced pluripotent stem cells (iPSCs) are differentiated under GMP conditions into midbrain dopaminergic neural progenitors or mature dopaminergic neurons, and then transplanted via stereotactic neurosurgical procedures into brain regions such as the striatum or putamen in patients with Parkinson’s disease. The goal is to replace lost dopaminergic neurons, restore local dopamine signaling, and improve motor symptoms. This therapy can be categorized into autologous patient-specific products, allogeneic off-the-shelf products, HLA-matched cell lines, and gene-edited universal donor cells. Key critical quality attributes include cell purity, proportion of A9 midbrain dopaminergic lineage, control of residual undifferentiated cells, tumorigenicity risk, dosing consistency, cryopreservation and thaw stability, and post-transplant survival and functional integration. The overall gross margin is approximately 58%.
Demand for this therapy is primarily driven by the limitations of current Parkinson’s disease treatments, including long-term fluctuations in drug efficacy, motor complications, and the lack of disease-modifying therapies. Dopaminergic neuron replacement directly targets the underlying loss of dopaminergic neurons and differs fundamentally from levodopa therapy, dopamine receptor agonists, or deep brain stimulation (DBS). It is particularly suited for moderate-to-advanced patients with insufficient drug response or those meeting surgical intervention criteria.
Product development is focused on cell sourcing strategy, immune compatibility, manufacturing consistency, and post-transplant functional integration. Autologous approaches can reduce immune rejection and the need for long-term immunosuppression but involve longer production timelines and higher individualized manufacturing costs. Allogeneic off-the-shelf approaches offer scalability and standardization but require solutions for HLA matching, immune suppression management, residual undifferentiated cell control, and long-term safety monitoring. As Japan moves toward early commercialization, and programs in the United States, Europe, and China progress through regulatory or early clinical stages, competition is shifting from proof-of-concept validation toward manufacturing scale-up, quality release systems, and neurosurgical delivery platform optimization.
Regional opportunities are concentrated in major clinical centers in Japan, the United States, China, and Europe. In the short term, market expansion is constrained by surgical capacity, reimbursement pathways, long-term follow-up requirements, and regulatory timelines, resulting in a commercialization pace significantly slower than conventional pharmaceuticals. However, due to the high single-treatment value and potential for durable efficacy, companies that demonstrate stable real-world safety and sustained motor function improvement may establish strong barriers through indication segmentation, construction of allogeneic cell banks, and integration with specialized neurosurgical networks.
Report Scope
LPI (LP Information)' newest research report, the “iPSC-Derived Dopaminergic Neuron Therapy Industry Forecast” looks at past sales and reviews total world iPSC-Derived Dopaminergic Neuron Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected iPSC-Derived Dopaminergic Neuron Therapy sales for 2026 through 2032. With iPSC-Derived Dopaminergic Neuron Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC-Derived Dopaminergic Neuron Therapy industry.
This Insight Report provides a comprehensive analysis of the global iPSC-Derived Dopaminergic Neuron Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on iPSC-Derived Dopaminergic Neuron Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC-Derived Dopaminergic Neuron Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC-Derived Dopaminergic Neuron Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC-Derived Dopaminergic Neuron Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of iPSC-Derived Dopaminergic Neuron Therapy market by product type, application, key players and key regions and countries.
iPSC-Derived Dopaminergic Neuron Therapy refers to a regenerative cell therapy approach in which induced pluripotent stem cells (iPSCs) are differentiated under GMP conditions into midbrain dopaminergic neural progenitors or mature dopaminergic neurons, and then transplanted via stereotactic neurosurgical procedures into brain regions such as the striatum or putamen in patients with Parkinson’s disease. The goal is to replace lost dopaminergic neurons, restore local dopamine signaling, and improve motor symptoms. This therapy can be categorized into autologous patient-specific products, allogeneic off-the-shelf products, HLA-matched cell lines, and gene-edited universal donor cells. Key critical quality attributes include cell purity, proportion of A9 midbrain dopaminergic lineage, control of residual undifferentiated cells, tumorigenicity risk, dosing consistency, cryopreservation and thaw stability, and post-transplant survival and functional integration. The overall gross margin is approximately 58%.
Demand for this therapy is primarily driven by the limitations of current Parkinson’s disease treatments, including long-term fluctuations in drug efficacy, motor complications, and the lack of disease-modifying therapies. Dopaminergic neuron replacement directly targets the underlying loss of dopaminergic neurons and differs fundamentally from levodopa therapy, dopamine receptor agonists, or deep brain stimulation (DBS). It is particularly suited for moderate-to-advanced patients with insufficient drug response or those meeting surgical intervention criteria.
Product development is focused on cell sourcing strategy, immune compatibility, manufacturing consistency, and post-transplant functional integration. Autologous approaches can reduce immune rejection and the need for long-term immunosuppression but involve longer production timelines and higher individualized manufacturing costs. Allogeneic off-the-shelf approaches offer scalability and standardization but require solutions for HLA matching, immune suppression management, residual undifferentiated cell control, and long-term safety monitoring. As Japan moves toward early commercialization, and programs in the United States, Europe, and China progress through regulatory or early clinical stages, competition is shifting from proof-of-concept validation toward manufacturing scale-up, quality release systems, and neurosurgical delivery platform optimization.
Regional opportunities are concentrated in major clinical centers in Japan, the United States, China, and Europe. In the short term, market expansion is constrained by surgical capacity, reimbursement pathways, long-term follow-up requirements, and regulatory timelines, resulting in a commercialization pace significantly slower than conventional pharmaceuticals. However, due to the high single-treatment value and potential for durable efficacy, companies that demonstrate stable real-world safety and sustained motor function improvement may establish strong barriers through indication segmentation, construction of allogeneic cell banks, and integration with specialized neurosurgical networks.
Report Scope
LPI (LP Information)' newest research report, the “iPSC-Derived Dopaminergic Neuron Therapy Industry Forecast” looks at past sales and reviews total world iPSC-Derived Dopaminergic Neuron Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected iPSC-Derived Dopaminergic Neuron Therapy sales for 2026 through 2032. With iPSC-Derived Dopaminergic Neuron Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC-Derived Dopaminergic Neuron Therapy industry.
This Insight Report provides a comprehensive analysis of the global iPSC-Derived Dopaminergic Neuron Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on iPSC-Derived Dopaminergic Neuron Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC-Derived Dopaminergic Neuron Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC-Derived Dopaminergic Neuron Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC-Derived Dopaminergic Neuron Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of iPSC-Derived Dopaminergic Neuron Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Autologous Patient-Specific Therapy
- HLA-Matched Allogeneic Therapy
- Standard Allogeneic Off-The-Shelf Therapy
- Gene-Edited Universal Therapy
- Other Donor Source Therapy
Segmentation by Cell Maturation Stage:
- Early Neural Progenitor Product
- Midbrain Dopaminergic Progenitor Product
- Dopamine Neuron Precursor Product
- Mature Dopaminergic Neuron Product
- Other Cell Stage Product
Segmentation by Formulation and Delivery:
- Fresh Cell Suspension
- Cryopreserved Cell Suspension
- Ready-to-Use Injection
- Device-Assisted Stereotactic Implantation
- Other Formulation and Delivery
Segmentation by Development Stage:
- Commercial or Conditional Approval
- Registrational or Phase III
- Phase II
- Phase I/II
- Phase I
- Preclinical
Segmentation by Application:
- Advanced Parkinson's Disease
- Early-Onset Parkinson's Disease
- Idiopathic Parkinson's Disease
- Levodopa-Inadequate Response Patients
- Regenerative Neurology Clinical Research
- Other Neurodegenerative Disease Research
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sumitomo Pharma
- RACTHERA
- Aspen Neuroscience
- XellSmart Bio-Pharmaceutical
- Shanghai UniXell Biotechnology
- iRegene Therapeutics
- iCamuno Biotherapeutics
- Kenai Therapeutics
- Mass General Brigham
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size (2021-2032)
2.1.2 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for iPSC-Derived Dopaminergic Neuron Therapy by Country/Region (2021, 2025 & 2032)
2.2 iPSC-Derived Dopaminergic Neuron Therapy Segment by Type
2.2.1 Autologous Patient-Specific Therapy
2.2.2 HLA-Matched Allogeneic Therapy
2.2.3 Standard Allogeneic Off-The-Shelf Therapy
2.2.4 Gene-Edited Universal Therapy
2.2.5 Other Donor Source Therapy
2.2.6 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type
2.2.6.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
2.3 iPSC-Derived Dopaminergic Neuron Therapy Segment by Cell Maturation Stage
2.3.1 Early Neural Progenitor Product
2.3.2 Midbrain Dopaminergic Progenitor Product
2.3.3 Dopamine Neuron Precursor Product
2.3.4 Mature Dopaminergic Neuron Product
2.3.5 Other Cell Stage Product
2.3.6 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Cell Maturation Stage
2.3.6.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Cell Maturation Stage (2021 VS 2025 VS 2032)
2.3.6.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Cell Maturation Stage (2021-2026)
2.4 iPSC-Derived Dopaminergic Neuron Therapy Segment by Formulation and Delivery
2.4.1 Fresh Cell Suspension
2.4.2 Cryopreserved Cell Suspension
2.4.3 Ready-to-Use Injection
2.4.4 Device-Assisted Stereotactic Implantation
2.4.5 Other Formulation and Delivery
2.4.6 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Formulation and Delivery
2.4.6.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Formulation and Delivery (2021 VS 2025 VS 2032)
2.4.6.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Formulation and Delivery (2021-2026)
2.5 iPSC-Derived Dopaminergic Neuron Therapy Segment by Development Stage
2.5.1 Commercial or Conditional Approval
2.5.2 Registrational or Phase III
2.5.3 Phase II
2.5.4 Phase I/II
2.5.5 Phase I
2.5.6 Preclinical
2.5.7 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Development Stage
2.5.7.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Development Stage (2021 VS 2025 VS 2032)
2.5.7.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Development Stage (2021-2026)
2.6 iPSC-Derived Dopaminergic Neuron Therapy Segment by Application
2.6.1 Advanced Parkinson's Disease
2.6.2 Early-Onset Parkinson's Disease
2.6.3 Idiopathic Parkinson's Disease
2.6.4 Levodopa-Inadequate Response Patients
2.6.5 Regenerative Neurology Clinical Research
2.6.6 Other Neurodegenerative Disease Research
2.6.7 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application
2.6.7.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.6.7.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
3 IPSC-DERIVED DOPAMINERGIC NEURON THERAPY MARKET SIZE BY PLAYER
3.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Player
3.1.1 Global iPSC-Derived Dopaminergic Neuron Therapy Revenue by Player (2021-2026)
3.1.2 Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Player (2021-2026)
3.2 Global iPSC-Derived Dopaminergic Neuron Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IPSC-DERIVED DOPAMINERGIC NEURON THERAPY BY REGION
4.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026)
4.2 Global iPSC-Derived Dopaminergic Neuron Therapy Annual Revenue by Country/Region (2021-2026)
4.3 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
4.4 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
4.5 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
4.6 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026)
5.2 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
5.3 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026)
6.2 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
6.3 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026)
7.2 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
7.3 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy by Region (2021-2026)
8.2 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
8.3 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IPSC-DERIVED DOPAMINERGIC NEURON THERAPY MARKET FORECAST
10.1 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.1.1 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.1.2 Americas iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.1.3 APAC iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.1.4 Europe iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.1.5 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2 Americas iPSC-Derived Dopaminergic Neuron Therapy Forecast by Country (2027-2032)
10.2.1 United States Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2.2 Canada Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2.3 Mexico Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2.4 Brazil Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3 APAC iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.3.1 China iPSC-Derived Dopaminergic Neuron Therapy Market Forecast
10.3.2 Japan Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.3 Korea Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.4 Southeast Asia Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.5 India Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.6 Australia Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4 Europe iPSC-Derived Dopaminergic Neuron Therapy Forecast by Country (2027-2032)
10.4.1 Germany Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.2 France Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.3 UK Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.4 Italy Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.5 Russia Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.5.1 Egypt Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5.2 South Africa Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5.3 Israel Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5.4 Turkey Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.6 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Type (2027-2032)
10.7 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Application (2027-2032)
10.7.1 GCC Countries Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sumitomo Pharma
11.1.1 Sumitomo Pharma Company Information
11.1.2 Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.1.3 Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sumitomo Pharma Main Business Overview
11.1.5 Sumitomo Pharma Latest Developments
11.2 RACTHERA
11.2.1 RACTHERA Company Information
11.2.2 RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.2.3 RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 RACTHERA Main Business Overview
11.2.5 RACTHERA Latest Developments
11.3 Aspen Neuroscience
11.3.1 Aspen Neuroscience Company Information
11.3.2 Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.3.3 Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Aspen Neuroscience Main Business Overview
11.3.5 Aspen Neuroscience Latest Developments
11.4 XellSmart Bio-Pharmaceutical
11.4.1 XellSmart Bio-Pharmaceutical Company Information
11.4.2 XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.4.3 XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 XellSmart Bio-Pharmaceutical Main Business Overview
11.4.5 XellSmart Bio-Pharmaceutical Latest Developments
11.5 Shanghai UniXell Biotechnology
11.5.1 Shanghai UniXell Biotechnology Company Information
11.5.2 Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.5.3 Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Shanghai UniXell Biotechnology Main Business Overview
11.5.5 Shanghai UniXell Biotechnology Latest Developments
11.6 iRegene Therapeutics
11.6.1 iRegene Therapeutics Company Information
11.6.2 iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.6.3 iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 iRegene Therapeutics Main Business Overview
11.6.5 iRegene Therapeutics Latest Developments
11.7 iCamuno Biotherapeutics
11.7.1 iCamuno Biotherapeutics Company Information
11.7.2 iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.7.3 iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 iCamuno Biotherapeutics Main Business Overview
11.7.5 iCamuno Biotherapeutics Latest Developments
11.8 Kenai Therapeutics
11.8.1 Kenai Therapeutics Company Information
11.8.2 Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.8.3 Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Kenai Therapeutics Main Business Overview
11.8.5 Kenai Therapeutics Latest Developments
11.9 Mass General Brigham
11.9.1 Mass General Brigham Company Information
11.9.2 Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.9.3 Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Mass General Brigham Main Business Overview
11.9.5 Mass General Brigham Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size (2021-2032)
2.1.2 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for iPSC-Derived Dopaminergic Neuron Therapy by Country/Region (2021, 2025 & 2032)
2.2 iPSC-Derived Dopaminergic Neuron Therapy Segment by Type
2.2.1 Autologous Patient-Specific Therapy
2.2.2 HLA-Matched Allogeneic Therapy
2.2.3 Standard Allogeneic Off-The-Shelf Therapy
2.2.4 Gene-Edited Universal Therapy
2.2.5 Other Donor Source Therapy
2.2.6 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type
2.2.6.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
2.3 iPSC-Derived Dopaminergic Neuron Therapy Segment by Cell Maturation Stage
2.3.1 Early Neural Progenitor Product
2.3.2 Midbrain Dopaminergic Progenitor Product
2.3.3 Dopamine Neuron Precursor Product
2.3.4 Mature Dopaminergic Neuron Product
2.3.5 Other Cell Stage Product
2.3.6 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Cell Maturation Stage
2.3.6.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Cell Maturation Stage (2021 VS 2025 VS 2032)
2.3.6.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Cell Maturation Stage (2021-2026)
2.4 iPSC-Derived Dopaminergic Neuron Therapy Segment by Formulation and Delivery
2.4.1 Fresh Cell Suspension
2.4.2 Cryopreserved Cell Suspension
2.4.3 Ready-to-Use Injection
2.4.4 Device-Assisted Stereotactic Implantation
2.4.5 Other Formulation and Delivery
2.4.6 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Formulation and Delivery
2.4.6.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Formulation and Delivery (2021 VS 2025 VS 2032)
2.4.6.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Formulation and Delivery (2021-2026)
2.5 iPSC-Derived Dopaminergic Neuron Therapy Segment by Development Stage
2.5.1 Commercial or Conditional Approval
2.5.2 Registrational or Phase III
2.5.3 Phase II
2.5.4 Phase I/II
2.5.5 Phase I
2.5.6 Preclinical
2.5.7 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Development Stage
2.5.7.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Development Stage (2021 VS 2025 VS 2032)
2.5.7.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Development Stage (2021-2026)
2.6 iPSC-Derived Dopaminergic Neuron Therapy Segment by Application
2.6.1 Advanced Parkinson's Disease
2.6.2 Early-Onset Parkinson's Disease
2.6.3 Idiopathic Parkinson's Disease
2.6.4 Levodopa-Inadequate Response Patients
2.6.5 Regenerative Neurology Clinical Research
2.6.6 Other Neurodegenerative Disease Research
2.6.7 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application
2.6.7.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.6.7.2 Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
3 IPSC-DERIVED DOPAMINERGIC NEURON THERAPY MARKET SIZE BY PLAYER
3.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Player
3.1.1 Global iPSC-Derived Dopaminergic Neuron Therapy Revenue by Player (2021-2026)
3.1.2 Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Player (2021-2026)
3.2 Global iPSC-Derived Dopaminergic Neuron Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IPSC-DERIVED DOPAMINERGIC NEURON THERAPY BY REGION
4.1 iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026)
4.2 Global iPSC-Derived Dopaminergic Neuron Therapy Annual Revenue by Country/Region (2021-2026)
4.3 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
4.4 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
4.5 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
4.6 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026)
5.2 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
5.3 Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026)
6.2 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
6.3 APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026)
7.2 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
7.3 Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy by Region (2021-2026)
8.2 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026)
8.3 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IPSC-DERIVED DOPAMINERGIC NEURON THERAPY MARKET FORECAST
10.1 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.1.1 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.1.2 Americas iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.1.3 APAC iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.1.4 Europe iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.1.5 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2 Americas iPSC-Derived Dopaminergic Neuron Therapy Forecast by Country (2027-2032)
10.2.1 United States Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2.2 Canada Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2.3 Mexico Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.2.4 Brazil Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3 APAC iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.3.1 China iPSC-Derived Dopaminergic Neuron Therapy Market Forecast
10.3.2 Japan Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.3 Korea Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.4 Southeast Asia Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.5 India Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.3.6 Australia Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4 Europe iPSC-Derived Dopaminergic Neuron Therapy Forecast by Country (2027-2032)
10.4.1 Germany Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.2 France Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.3 UK Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.4 Italy Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.4.5 Russia Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5 Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Forecast by Region (2027-2032)
10.5.1 Egypt Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5.2 South Africa Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5.3 Israel Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.5.4 Turkey Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
10.6 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Type (2027-2032)
10.7 Global iPSC-Derived Dopaminergic Neuron Therapy Forecast by Application (2027-2032)
10.7.1 GCC Countries Market iPSC-Derived Dopaminergic Neuron Therapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sumitomo Pharma
11.1.1 Sumitomo Pharma Company Information
11.1.2 Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.1.3 Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sumitomo Pharma Main Business Overview
11.1.5 Sumitomo Pharma Latest Developments
11.2 RACTHERA
11.2.1 RACTHERA Company Information
11.2.2 RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.2.3 RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 RACTHERA Main Business Overview
11.2.5 RACTHERA Latest Developments
11.3 Aspen Neuroscience
11.3.1 Aspen Neuroscience Company Information
11.3.2 Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.3.3 Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Aspen Neuroscience Main Business Overview
11.3.5 Aspen Neuroscience Latest Developments
11.4 XellSmart Bio-Pharmaceutical
11.4.1 XellSmart Bio-Pharmaceutical Company Information
11.4.2 XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.4.3 XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 XellSmart Bio-Pharmaceutical Main Business Overview
11.4.5 XellSmart Bio-Pharmaceutical Latest Developments
11.5 Shanghai UniXell Biotechnology
11.5.1 Shanghai UniXell Biotechnology Company Information
11.5.2 Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.5.3 Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Shanghai UniXell Biotechnology Main Business Overview
11.5.5 Shanghai UniXell Biotechnology Latest Developments
11.6 iRegene Therapeutics
11.6.1 iRegene Therapeutics Company Information
11.6.2 iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.6.3 iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 iRegene Therapeutics Main Business Overview
11.6.5 iRegene Therapeutics Latest Developments
11.7 iCamuno Biotherapeutics
11.7.1 iCamuno Biotherapeutics Company Information
11.7.2 iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.7.3 iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 iCamuno Biotherapeutics Main Business Overview
11.7.5 iCamuno Biotherapeutics Latest Developments
11.8 Kenai Therapeutics
11.8.1 Kenai Therapeutics Company Information
11.8.2 Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.8.3 Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Kenai Therapeutics Main Business Overview
11.8.5 Kenai Therapeutics Latest Developments
11.9 Mass General Brigham
11.9.1 Mass General Brigham Company Information
11.9.2 Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Product Offered
11.9.3 Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Mass General Brigham Main Business Overview
11.9.5 Mass General Brigham Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. iPSC-Derived Dopaminergic Neuron Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Autologous Patient-Specific Therapy
Table 4. Major Players of HLA-Matched Allogeneic Therapy
Table 5. Major Players of Standard Allogeneic Off-The-Shelf Therapy
Table 6. Major Players of Gene-Edited Universal Therapy
Table 7. Major Players of Other Donor Source Therapy
Table 8. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 10. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Early Neural Progenitor Product
Table 12. Major Players of Midbrain Dopaminergic Progenitor Product
Table 13. Major Players of Dopamine Neuron Precursor Product
Table 14. Major Players of Mature Dopaminergic Neuron Product
Table 15. Major Players of Other Cell Stage Product
Table 16. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Cell Maturation Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Cell Maturation Stage (2021-2026) & ($ millions)
Table 18. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Cell Maturation Stage (2021-2026)
Table 19. Major Players of Fresh Cell Suspension
Table 20. Major Players of Cryopreserved Cell Suspension
Table 21. Major Players of Ready-to-Use Injection
Table 22. Major Players of Device-Assisted Stereotactic Implantation
Table 23. Major Players of Other Formulation and Delivery
Table 24. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Formulation and Delivery (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Formulation and Delivery (2021-2026) & ($ millions)
Table 26. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Formulation and Delivery (2021-2026)
Table 27. Major Players of Commercial or Conditional Approval
Table 28. Major Players of Registrational or Phase III
Table 29. Major Players of Phase II
Table 30. Major Players of Phase I/II
Table 31. Major Players of Phase I
Table 32. Major Players of Preclinical
Table 33. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Development Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 34. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Development Stage (2021-2026) & ($ millions)
Table 35. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Development Stage (2021-2026)
Table 36. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 37. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 38. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Table 39. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue by Player (2021-2026) & ($ millions)
Table 40. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Player (2021-2026)
Table 41. iPSC-Derived Dopaminergic Neuron Therapy Key Players Head office and Products Offered
Table 42. iPSC-Derived Dopaminergic Neuron Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 43. New Products and Potential Entrants
Table 44. Mergers & Acquisitions, Expansion
Table 45. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026) & ($ millions)
Table 46. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Table 47. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026) & ($ millions)
Table 50. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Country (2021-2026)
Table 51. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 52. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Table 53. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 54. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Table 55. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026) & ($ millions)
Table 56. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Table 57. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 58. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 59. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026) & ($ millions)
Table 60. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Country (2021-2026)
Table 61. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 62. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 63. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026) & ($ millions)
Table 64. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 65. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 66. Key Market Drivers & Growth Opportunities of iPSC-Derived Dopaminergic Neuron Therapy
Table 67. Key Market Challenges & Risks of iPSC-Derived Dopaminergic Neuron Therapy
Table 68. Key Industry Trends of iPSC-Derived Dopaminergic Neuron Therapy
Table 69. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Forecast by Region (2027-2032) & ($ millions)
Table 70. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share Forecast by Region (2027-2032)
Table 71. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Forecast by Type (2027-2032) & ($ millions)
Table 72. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Forecast by Application (2027-2032) & ($ millions)
Table 73. Sumitomo Pharma Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 74. Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 75. Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Sumitomo Pharma Main Business
Table 77. Sumitomo Pharma Latest Developments
Table 78. RACTHERA Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 79. RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 80. RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. RACTHERA Main Business
Table 82. RACTHERA Latest Developments
Table 83. Aspen Neuroscience Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 84. Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 85. Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Aspen Neuroscience Main Business
Table 87. Aspen Neuroscience Latest Developments
Table 88. XellSmart Bio-Pharmaceutical Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 89. XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 90. XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. XellSmart Bio-Pharmaceutical Main Business
Table 92. XellSmart Bio-Pharmaceutical Latest Developments
Table 93. Shanghai UniXell Biotechnology Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 94. Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 95. Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Shanghai UniXell Biotechnology Main Business
Table 97. Shanghai UniXell Biotechnology Latest Developments
Table 98. iRegene Therapeutics Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 99. iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 100. iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. iRegene Therapeutics Main Business
Table 102. iRegene Therapeutics Latest Developments
Table 103. iCamuno Biotherapeutics Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 104. iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 105. iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. iCamuno Biotherapeutics Main Business
Table 107. iCamuno Biotherapeutics Latest Developments
Table 108. Kenai Therapeutics Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 109. Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 110. Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Kenai Therapeutics Main Business
Table 112. Kenai Therapeutics Latest Developments
Table 113. Mass General Brigham Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 114. Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 115. Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. Mass General Brigham Main Business
Table 117. Mass General Brigham Latest Developments
Table 1. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. iPSC-Derived Dopaminergic Neuron Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Autologous Patient-Specific Therapy
Table 4. Major Players of HLA-Matched Allogeneic Therapy
Table 5. Major Players of Standard Allogeneic Off-The-Shelf Therapy
Table 6. Major Players of Gene-Edited Universal Therapy
Table 7. Major Players of Other Donor Source Therapy
Table 8. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 10. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Early Neural Progenitor Product
Table 12. Major Players of Midbrain Dopaminergic Progenitor Product
Table 13. Major Players of Dopamine Neuron Precursor Product
Table 14. Major Players of Mature Dopaminergic Neuron Product
Table 15. Major Players of Other Cell Stage Product
Table 16. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Cell Maturation Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Cell Maturation Stage (2021-2026) & ($ millions)
Table 18. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Cell Maturation Stage (2021-2026)
Table 19. Major Players of Fresh Cell Suspension
Table 20. Major Players of Cryopreserved Cell Suspension
Table 21. Major Players of Ready-to-Use Injection
Table 22. Major Players of Device-Assisted Stereotactic Implantation
Table 23. Major Players of Other Formulation and Delivery
Table 24. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Formulation and Delivery (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Formulation and Delivery (2021-2026) & ($ millions)
Table 26. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Formulation and Delivery (2021-2026)
Table 27. Major Players of Commercial or Conditional Approval
Table 28. Major Players of Registrational or Phase III
Table 29. Major Players of Phase II
Table 30. Major Players of Phase I/II
Table 31. Major Players of Phase I
Table 32. Major Players of Preclinical
Table 33. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Development Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 34. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Development Stage (2021-2026) & ($ millions)
Table 35. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Development Stage (2021-2026)
Table 36. iPSC-Derived Dopaminergic Neuron Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 37. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 38. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Table 39. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue by Player (2021-2026) & ($ millions)
Table 40. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Player (2021-2026)
Table 41. iPSC-Derived Dopaminergic Neuron Therapy Key Players Head office and Products Offered
Table 42. iPSC-Derived Dopaminergic Neuron Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 43. New Products and Potential Entrants
Table 44. Mergers & Acquisitions, Expansion
Table 45. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026) & ($ millions)
Table 46. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Table 47. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026) & ($ millions)
Table 50. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Country (2021-2026)
Table 51. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 52. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Table 53. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 54. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Table 55. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026) & ($ millions)
Table 56. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Table 57. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 58. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 59. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Country (2021-2026) & ($ millions)
Table 60. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Country (2021-2026)
Table 61. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 62. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 63. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Region (2021-2026) & ($ millions)
Table 64. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Type (2021-2026) & ($ millions)
Table 65. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size by Application (2021-2026) & ($ millions)
Table 66. Key Market Drivers & Growth Opportunities of iPSC-Derived Dopaminergic Neuron Therapy
Table 67. Key Market Challenges & Risks of iPSC-Derived Dopaminergic Neuron Therapy
Table 68. Key Industry Trends of iPSC-Derived Dopaminergic Neuron Therapy
Table 69. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Forecast by Region (2027-2032) & ($ millions)
Table 70. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share Forecast by Region (2027-2032)
Table 71. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Forecast by Type (2027-2032) & ($ millions)
Table 72. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Forecast by Application (2027-2032) & ($ millions)
Table 73. Sumitomo Pharma Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 74. Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 75. Sumitomo Pharma iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Sumitomo Pharma Main Business
Table 77. Sumitomo Pharma Latest Developments
Table 78. RACTHERA Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 79. RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 80. RACTHERA iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. RACTHERA Main Business
Table 82. RACTHERA Latest Developments
Table 83. Aspen Neuroscience Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 84. Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 85. Aspen Neuroscience iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Aspen Neuroscience Main Business
Table 87. Aspen Neuroscience Latest Developments
Table 88. XellSmart Bio-Pharmaceutical Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 89. XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 90. XellSmart Bio-Pharmaceutical iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. XellSmart Bio-Pharmaceutical Main Business
Table 92. XellSmart Bio-Pharmaceutical Latest Developments
Table 93. Shanghai UniXell Biotechnology Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 94. Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 95. Shanghai UniXell Biotechnology iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Shanghai UniXell Biotechnology Main Business
Table 97. Shanghai UniXell Biotechnology Latest Developments
Table 98. iRegene Therapeutics Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 99. iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 100. iRegene Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. iRegene Therapeutics Main Business
Table 102. iRegene Therapeutics Latest Developments
Table 103. iCamuno Biotherapeutics Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 104. iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 105. iCamuno Biotherapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. iCamuno Biotherapeutics Main Business
Table 107. iCamuno Biotherapeutics Latest Developments
Table 108. Kenai Therapeutics Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 109. Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 110. Kenai Therapeutics iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Kenai Therapeutics Main Business
Table 112. Kenai Therapeutics Latest Developments
Table 113. Mass General Brigham Details, Company Type, iPSC-Derived Dopaminergic Neuron Therapy Area Served and Its Competitors
Table 114. Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Product Offered
Table 115. Mass General Brigham iPSC-Derived Dopaminergic Neuron Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. Mass General Brigham Main Business
Table 117. Mass General Brigham Latest Developments
LIST OF FIGURES
Figure 1. iPSC-Derived Dopaminergic Neuron Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. iPSC-Derived Dopaminergic Neuron Therapy Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. iPSC-Derived Dopaminergic Neuron Therapy Sales Market Share by Country/Region (2025)
Figure 8. iPSC-Derived Dopaminergic Neuron Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type in 2025
Figure 10. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Cell Maturation Stage in 2025
Figure 11. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Formulation and Delivery in 2025
Figure 12. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Development Stage in 2025
Figure 13. iPSC-Derived Dopaminergic Neuron Therapy in Advanced Parkinson's Disease
Figure 14. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Advanced Parkinson's Disease (2021-2026) & ($ millions)
Figure 15. iPSC-Derived Dopaminergic Neuron Therapy in Early-Onset Parkinson's Disease
Figure 16. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Early-Onset Parkinson's Disease (2021-2026) & ($ millions)
Figure 17. iPSC-Derived Dopaminergic Neuron Therapy in Idiopathic Parkinson's Disease
Figure 18. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Idiopathic Parkinson's Disease (2021-2026) & ($ millions)
Figure 19. iPSC-Derived Dopaminergic Neuron Therapy in Levodopa-Inadequate Response Patients
Figure 20. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Levodopa-Inadequate Response Patients (2021-2026) & ($ millions)
Figure 21. iPSC-Derived Dopaminergic Neuron Therapy in Regenerative Neurology Clinical Research
Figure 22. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Regenerative Neurology Clinical Research (2021-2026) & ($ millions)
Figure 23. iPSC-Derived Dopaminergic Neuron Therapy in Other Neurodegenerative Disease Research
Figure 24. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Other Neurodegenerative Disease Research (2021-2026) & ($ millions)
Figure 25. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application in 2025
Figure 26. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Player in 2025
Figure 27. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Figure 28. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 29. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 30. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 31. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 32. Americas iPSC-Derived Dopaminergic Neuron Therapy Value Market Share by Country in 2025
Figure 33. United States iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 34. Canada iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 35. Mexico iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 36. Brazil iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 37. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region in 2025
Figure 38. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Figure 39. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Figure 40. China iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 41. Japan iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 42. South Korea iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 43. Southeast Asia iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 44. India iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 45. Australia iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 46. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Country in 2025
Figure 47. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Figure 48. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Figure 49. Germany iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 50. France iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 51. UK iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 52. Italy iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 53. Russia iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 54. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Figure 55. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Figure 56. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Figure 57. Egypt iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 58. South Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 59. Israel iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 60. Turkey iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 61. GCC Countries iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 62. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 63. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 64. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 65. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 66. United States iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 67. Canada iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 68. Mexico iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 69. Brazil iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 70. China iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 71. Japan iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 72. Korea iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 73. Southeast Asia iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 74. India iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 75. Australia iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 76. Germany iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 77. France iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 78. UK iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 79. Italy iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 80. Russia iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 81. Egypt iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 82. South Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 83. Israel iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 84. Turkey iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 85. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share Forecast by Type (2027-2032)
Figure 86. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share Forecast by Application (2027-2032)
Figure 87. GCC Countries iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 1. iPSC-Derived Dopaminergic Neuron Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. iPSC-Derived Dopaminergic Neuron Therapy Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. iPSC-Derived Dopaminergic Neuron Therapy Sales Market Share by Country/Region (2025)
Figure 8. iPSC-Derived Dopaminergic Neuron Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type in 2025
Figure 10. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Cell Maturation Stage in 2025
Figure 11. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Formulation and Delivery in 2025
Figure 12. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Development Stage in 2025
Figure 13. iPSC-Derived Dopaminergic Neuron Therapy in Advanced Parkinson's Disease
Figure 14. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Advanced Parkinson's Disease (2021-2026) & ($ millions)
Figure 15. iPSC-Derived Dopaminergic Neuron Therapy in Early-Onset Parkinson's Disease
Figure 16. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Early-Onset Parkinson's Disease (2021-2026) & ($ millions)
Figure 17. iPSC-Derived Dopaminergic Neuron Therapy in Idiopathic Parkinson's Disease
Figure 18. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Idiopathic Parkinson's Disease (2021-2026) & ($ millions)
Figure 19. iPSC-Derived Dopaminergic Neuron Therapy in Levodopa-Inadequate Response Patients
Figure 20. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Levodopa-Inadequate Response Patients (2021-2026) & ($ millions)
Figure 21. iPSC-Derived Dopaminergic Neuron Therapy in Regenerative Neurology Clinical Research
Figure 22. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Regenerative Neurology Clinical Research (2021-2026) & ($ millions)
Figure 23. iPSC-Derived Dopaminergic Neuron Therapy in Other Neurodegenerative Disease Research
Figure 24. Global iPSC-Derived Dopaminergic Neuron Therapy Market: Other Neurodegenerative Disease Research (2021-2026) & ($ millions)
Figure 25. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application in 2025
Figure 26. Global iPSC-Derived Dopaminergic Neuron Therapy Revenue Market Share by Player in 2025
Figure 27. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Figure 28. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 29. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 30. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 31. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size 2021-2026 ($ millions)
Figure 32. Americas iPSC-Derived Dopaminergic Neuron Therapy Value Market Share by Country in 2025
Figure 33. United States iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 34. Canada iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 35. Mexico iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 36. Brazil iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 37. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region in 2025
Figure 38. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Figure 39. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Figure 40. China iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 41. Japan iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 42. South Korea iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 43. Southeast Asia iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 44. India iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 45. Australia iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 46. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Country in 2025
Figure 47. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Figure 48. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Figure 49. Germany iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 50. France iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 51. UK iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 52. Italy iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 53. Russia iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 54. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Region (2021-2026)
Figure 55. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Type (2021-2026)
Figure 56. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share by Application (2021-2026)
Figure 57. Egypt iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 58. South Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 59. Israel iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 60. Turkey iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 61. GCC Countries iPSC-Derived Dopaminergic Neuron Therapy Market Size Growth 2021-2026 ($ millions)
Figure 62. Americas iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 63. APAC iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 64. Europe iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 65. Middle East & Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 66. United States iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 67. Canada iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 68. Mexico iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 69. Brazil iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 70. China iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 71. Japan iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 72. Korea iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 73. Southeast Asia iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 74. India iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 75. Australia iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 76. Germany iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 77. France iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 78. UK iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 79. Italy iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 80. Russia iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 81. Egypt iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 82. South Africa iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 83. Israel iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 84. Turkey iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
Figure 85. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share Forecast by Type (2027-2032)
Figure 86. Global iPSC-Derived Dopaminergic Neuron Therapy Market Size Market Share Forecast by Application (2027-2032)
Figure 87. GCC Countries iPSC-Derived Dopaminergic Neuron Therapy Market Size 2027-2032 ($ millions)
